Acquisitions by Lupin

(Aranchika Kumari-PGMA1912)
Lupin’s Acquisition of GAVIS
• Lupin had announced the acquisition on July 23rd 2015.
• The acquisition enhances Lupin’s scale in the US generic market

 The generic company of LUPIN expanded by around 12 % . LUPIN

continue to expand the US generics sector by adding GAVIS to its portfolio.
About GAVIS
• New Jersey based GAVIS is a privately held company
• Specialized in formulation development, manufacturing, packaging,
sales, marketing, and distribution of pharmaceuticals products
• GAVIS has 62 ANDA filings pending approval with the US FDA and a
pipeline of over 65+ products under development.
• The acquisition creates the 5th largest pipeline of ANDA filings with
the US FDA, addressing a USD 63.8 billion market.
Key facts about the deal
• Company’s goal to expand and deepen their US presence
• highly skilled US based R&D organization of GAVIS complement
Lupin’s Coral Springs, Florida, inhalation R&D centre. 
• Funding for the deal will be fully committed from J.P. Morgan Chase
Bank.
• Immediately accretive to first full year of earnings
Pfizer-Hospira Acquisition
• Global Pharmaceutical giant Pfizer Inc. is set to acquire Hospira Inc.
• Pfizer Inc. and Hospira Inc. announced on 5th February, 2015
• The proposed acquisition is seen as an excellent strategic fit for Pfizer’s Global
Established Pharmaceutical (GEP) business
• Pfizer’s acquisition of Hospira aligns with Pfizer’s strategic priorities and is expected
to significantly enhance key growth areas of its GEP business
• Addition of biosimilars to portfolio
GSK – Tesaro Acquisition
• TESARO is an oncology-focused biopharmaceutical company
• GSK is a science-led global healthcare company with a special purpose: to help
people do more, feel better, live longer
• Acquisition will reinforce the pharmaceutical sector by enhancing the growth of
 oncology pipeline
 commercial presence
 access to new analytical capabilities